KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases (2016)

Rigel Pharmaceuticals has reported Capital Leases over the past 4 years, most recently at $238000.0 for Q4 2016.

  • Quarterly results put Capital Leases at $238000.0 for Q4 2016, down 93.12% from a year ago — trailing twelve months through Dec 2016 was $238000.0 (down 93.12% YoY), and the annual figure for FY2016 was $238000.0, down 93.12%.
  • Capital Leases for Q4 2016 was $238000.0 at Rigel Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over the last five years, Capital Leases for RIGL hit a ceiling of $6.5 million in Q4 2014 and a floor of $238000.0 in Q4 2016.
  • Median Capital Leases over the past 3 years was $3.5 million (2015), compared with a mean of $3.4 million.
  • Biggest five-year swings in Capital Leases: plummeted 46.49% in 2015 and later tumbled 93.12% in 2016.
  • Rigel Pharmaceuticals' Capital Leases stood at $6.5 million in 2014, then tumbled by 46.49% to $3.5 million in 2015, then tumbled by 93.12% to $238000.0 in 2016.
  • The last three reported values for Capital Leases were $238000.0 (Q4 2016), $1.1 million (Q3 2016), and $1.9 million (Q2 2016) per Business Quant data.